Angiodynamics (ANGO) Net Cash Flow (2010 - 2026)

Angiodynamics (ANGO) has reported Net Cash Flow for 17 consecutive years, with $16.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 54.29% year-over-year to $16.1 million; the trailing twelve-month figure through May 2026 stood at -$2.3 million (up 88.83% YoY), and the FY2026 full-year result was -$2.3 million, up 88.83% from the prior year.
• Net Cash Flow improved to $16.1 million in Q2 2026 per ANGO's latest filing, from -$4.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $17.6 million in Q1 2024 and bottomed at -$21.2 million in Q3 2024.
• Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of $1.6 million in 2023.
• The widest YoY moves for Net Cash Flow: up 10549.7% in 2024, down 263.41% in 2024.
• Over 5 years, Net Cash Flow stood at $5.1 million in 2022, then tumbled by 38.88% to $3.1 million in 2023, then slumped by 119.58% to -$611000.0 in 2024, then soared by 582.49% to $2.9 million in 2025, then surged by 445.25% to $16.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $16.1 million, -$4.0 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.